Settlement Agreements are Favored under North Carolina Law... or So We Thought: Problems with the Court of Appeals\u27 New Approach Allowing County Governments to Invalidate an Otherwise Binding Settlement Agreement Using North Carolina General Statute Section 159-28

This comment first examines the established law of settlement agreements in North Carolina, specifically relating to how such agreements are favored under the law, general enforcement of these agreements, and special rules concerning counties and municipalities. Second, it focuses on the requirements for a pre-audit certification under North Carolina General Statute section 159-28(a), the perplexing judicial interpretation of this statute by the North Carolina Court of Appeals, and the resulting inequitable status of the law that treats settlement agreements with county and municipal governments on a different playing field than those with a private entity. Finally, a proposal is offered to remedy the one-sided state of the law that now allows a county or municipal government to back out of a settlement agreement to which it would otherwise be bound

Settlement Agreements are Favored under North Carolina Law... or So We Thought: Problems with the Court of Appeals\u27 New Approach Allowing County Governments to Invalidate an Otherwise Binding Settlement Agreement Using North Carolina General Statute Section 159-28

This comment first examines the established law of settlement agreements in North Carolina, specifically relating to how such agreements are favored under the law, general enforcement of these agreements, and special rules concerning counties and municipalities. Second, it focuses on the requirements for a pre-audit certification under North Carolina General Statute section 159-28(a), the perplexing judicial interpretation of this statute by the North Carolina Court of Appeals, and the resulting inequitable status of the law that treats settlement agreements with county and municipal governments on a different playing field than those with a private entity. Finally, a proposal is offered to remedy the one-sided state of the law that now allows a county or municipal government to back out of a settlement agreement to which it would otherwise be bound

Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes.

Most patients with myelodysplastic syndromes (MDS) present with single or multiple lineage cytopenias in peripheral blood despite a hypercellular bone marrow. Thrombocytopenia, attributable to ineffective platelet production by dysfunctional megakaryocytes, has been estimated to occur in 40-65% of patients. However, there are hardly any studies on the clinical relevance of low platelet counts in MDS. We retrospectively analysed data from 2900 patients in the Duesseldorf MDS Registry who were diagnosed at our laboratory between 1982 and 2007. At the time of diagnosis, 43% of the patients had a platelet count lower than 100 000/microL. Platelets were lower than 20 000/microL in 7% of the patients, especially in those with advanced stages of MDS, who showed a higher frequency of thrombocytopenia and platelet transfusion dependency. On multivariate analysis, platelet anisometry, hypocellularity of megakaryopoiesis, maturational defects of megakaryocytes and platelets <20 000/microL were independent variables showing a statistically significant correlation (P < 0.05) with clinical signs of bleeding. Platelets lower than 100 000/microL were associated with significantly shortened survival (P < 0.00005), because of an increased risk of progression to acute myeloid leukaemia (AML) (30% vs. 21%) (P < 0.02) and bleeding (16% vs. 8%) (P = 0.0005). Thrombocytopenia is a strong predictor of short survival, with or without haemorrhagic complications

Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload

Between 2002 and 2008, a number of consensus statements and guidelines were developed by various groups around the world to educate healthcare professionals on the treatment of myelodysplastic syndromes (MDS), including the management of transfusional iron overload with iron chelation therapy. Guidelines have been developed by The Italian Society of Hematology, The UK MDS Guidelines Group, The Nagasaki Group, The National Comprehensive Cancer Network, and The MDS Foundation. These guidelines show that the approaches to managing iron overload in patients with MDS are region specific, differing in their recommendations for when iron chelation therapy should be initiated and strategies for the ongoing management of iron overload. The guidelines all agree that red blood cell transfusions are clinically beneficial to treat the symptomatic anemia in MDS, and that patients with low-risk MDS receiving transfusions are the most likely to benefit from iron chelation therapy

CHEMICAL CONTROL OF THE REDBAY AMBROSIA BEETLE, XYLEBORUS GLABRATUS, AND OTHER SCOLYTINAE (COLEOPTERA: CURCULIONIDAE)

A BSTRACT The redbay ambrosia beetle (RAB), Xyleborus glabratus Eichhoff (Coleoptera: Curculionidae: Scolytinae), is an adventive pest of Lauraceae in the southeastern U.S. This wood-boring insect vectors a lethal fungus, Raffaelea lauricola T. C. Harr., Fraedrich & Aghayeva , the causal agent of laurel wilt (LW) disease. The vector-pathogen complex is responsible for extensive mortality of native Persea trees in South Carolina, Georgia, and northern Florida, and now poses an imminent threat to the avocado ( Persea americana Mill.) industry in south Florida. While chemical control of the vector is not viewed as the primary solution, control tactics should be made available to Florida avocado growers. Field and laboratory tests were conducted using avocado bolts, potted avocado trees, and field grown swampbay trees ( Persea palustris (Raf.) Sarg.) treated with contact and systemic insecticides. Zeta-cypermethrin + bifenthrin and lambda-cyhalothrin + thiamethoxam provided the most consistent control of Scolytinae as contact insecticides, while methomyl, malathion, bifenthrin, and endosulfan were more variable in effectiveness. Avocado trees treated with fenpropathrin, cryolite Na Al fluoride, and lambda-cyhalothrin+thiametoxam had similar numbers of beetle entrance holes on treated trees as on the untreated control trees. No statistical differences were observed in disease severity on treated versus non-treated avocados or swampbay. Linear regressions between the number of RAB entrance holes per tree ( x) and LW disease severity ( y a ) and between RAB entrance holes per tree ( x) and recovery of R. lauricola ( y b ) were both significant. Key Words: Redbay ambrosia beetle, avocado, Persea , Xyleborus , Xylosandrus , Hypothenemus , chemical control R ESUMEN El cucarroncito de ambrosia del laurel, Xyleborus glabratus Eichhoff (Coleoptera: Curculionidae), es una plaga exótica de la familia Lauraceae que ha invadido el suroriente de los Estados Unidos. Este insecto barrenador es el vector del hongo, Raffaelea lauricola T.C. Harr., Fraedrich & Aghayeva, agente causal de la enfermedad del secamiento del laurel. El complejo vector-patógeno es responsable de una extensa mortalidad de arboles nativos del genero Persea en Carolina del Sur, Georgia y en el norte de Florida y representa una amenaza inminente para la industria del aguacate ( Persea americana Mill.) de Florida. Aunque el control químico no es la única solución a este problema, se estima que este tipo de opción de tác-ticas se debe ofrecer a los productores de aguacate. Se condujeron experimentos tanto en campo como en laboratorio utilizando troncos de aguacate, arboles de aguacate y arboles del laurel de la ciénaga ( P. palustris (Raf.) Sarg.), los cuales se trataron con insecticidas de contacto y sistémicos. En general, zetaciypermetrina + bifenthrina y lambda-cyalotrina + tiametoxam dieron un control consistente de los Scolytinae como insecticidas de contacto, mientras que metomíl, malatión y bifentrina y endosulfan dieron resultados variables. No hubo diferencias significativas en los orificios de entrada de los cucarroncitos cuando se trataron los arboles de aguacate con fenpropatrina, floruro de cryolita NA Al y lambda-cyalotrina-tiametoxam comparado con los arboles testigo. No se observaron diferencias estadísticas en cuanto a la severidad de la enfermedad entre árboles tratados y aquellos no tratados. Sin embargo, modelos de regresión lineal entre el número de orificios por árbol ( x

Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment.

Tyrosine kinase inhibitors represent today's treatment of choice in chronic myeloid leukemia (CML). Allogeneic hematopoietic stem cell transplantation (HSCT) is regarded as salvage therapy. This prospective randomized CML-study IIIA recruited 669 patients with newly diagnosed CML between July 1997 and January 2004 from 143 centers. Of these, 427 patients were considered eligible for HSCT and were randomized by availability of a matched family donor between primary HSCT (group A; N=166 patients) and best available drug treatment (group B; N=261). Primary end point was long-term survival. Survival probabilities were not different between groups A and B (10-year survival: 0.76 (95% confidence interval (CI): 0.69-0.82) vs 0.69 (95% CI: 0.61-0.76)), but influenced by disease and transplant risk. Patients with a low transplant risk showed superior survival compared with patients with high- (P<0.001) and non-high-risk disease (P=0.047) in group B; after entering blast crisis, survival was not different with or without HSCT. Significantly more patients in group A were in molecular remission (56% vs 39%; P=0.005) and free of drug treatment (56% vs 6%; P<0.001). Differences in symptoms and Karnofsky score were not significant. In the era of tyrosine kinase inhibitors, HSCT remains a valid option when both disease and transplant risk are considered